Search the Newsreel

Hollencrest Capital Management Purchases 8,921 Shares of Johnson & Johnson $JNJ

Hollencrest Capital Management significantly increased its stake in Johnson & Johnson (NYSE:JNJ) by 142% in the first quarter, acquiring an additional 8,921 shares to bring its total holdings to 15,204 shares valued at $3.7 million. This move coincides with increasing analyst optimism for JNJ, …

Meeder Advisory Services Inc. Acquires 4,916 Shares of Johnson & Johnson $JNJ

Meeder Advisory Services Inc. increased its stake in Johnson & Johnson by 8.3% in the first quarter, purchasing an additional 4,916 shares. This acquisition brings their total holdings to 63,813 shares, valued at $15.598 million, making J&J their 27th largest position. The article also …

Johnson & Johnson $JNJ Shares Sold by KBC Group NV

KBC Group NV significantly reduced its stake in Johnson & Johnson (JNJ) by selling over 1 million shares in the first quarter, though it still holds a substantial position. Despite this sale, Wall Street analysts maintain a "Moderate Buy" rating for JNJ with an …

Reading Between The Lines Of JNJ Stock’s Latest Call

Johnson & Johnson (JNJ) reported strong pharmaceutical growth, leading to a raised full-year guidance, but this masked a concerning slowdown in its MedTech division, particularly with its Abiomed heart pump business. Analysts questioned whether the booming Innovative Medicine segment can fully compensate for the …

Johnson & Johnson’s 68-week Trend Signal absorbs a 45.9M-share down week

JNJ slipped 1.5% in the latest week, but the broader profile remains constructive, with the stock still 8.7% above its weekly Trend Line and 85.2% through its 52-week range.

Lobbying Update: $1,440,000 of JOHNSON & JOHNSON SERVICES INC lobbying was just disclosed

A recent lobbying disclosure revealed that JOHNSON & JOHNSON SERVICES INC spent $1,440,000 in Q2 2026 on lobbying efforts focused on various legislative issues, including the National Defense Authorization Act, medical device electronic labeling, drug pricing, and intellectual property. The article also details recent …

Why Johnson & Johnson Is a Stock You Can Own Forever

Johnson & Johnson (JNJ) is presented as a stock ideal for long-term investors due to its strong balance sheet, 64-year dividend growth streak, and diversified healthcare business spanning pharmaceuticals and medical devices. The company's durability is evidenced by its consistent revenue growth across six …

Johnson & Johnson (JNJ) Buys Spine Tech And Wins FDA Nod For Heart Device

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. DePuy Synthes, part of Johnson & Johnson MedTech, has acquired spine surgery company Expanding Innovations, adding new expandable interbody technologies to its portfolio. Johnson & Johnson has …

Freedom Capital upgrades Johnson & Johnson stock rating on strong quarter

Freedom Capital upgraded Johnson & Johnson (NYSE:JNJ) to Buy from Hold and raised its price target to $280 due to strong quarterly performance, particularly in TREMFYA, CAPLYTA, and SPRAVATO revenues. The firm is now more confident J&J will surpass its $100 billion revenue target …

Johnson & Johnson (JNJ) Crosses $100 Billion As DePuy Synthes Buys Spine Tech

Johnson & Johnson (JNJ) has reached an annual revenue of over $100 billion for the first time, supported by strong Q2 results and raised guidance for 2026. This milestone is coupled with MedTech unit DePuy Synthes acquiring Expanding Innovations to bolster JNJ's presence in …

Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?

This article compares Johnson & Johnson and Eli Lilly and Company, two major pharmaceutical giants, as potential investments in 2026. While Johnson & Johnson offers stability and diversification across medical technology and pharmaceuticals, Eli Lilly presents a high-growth opportunity driven by its dominant position …

The Real Engine Behind Johnson & Johnson Stock’s Next Climb

Johnson & Johnson (JNJ) stock has paused after a significant run-up, leading investors to question its next growth driver. The article suggests that while one segment faces a slowdown, the Innovative Medicine division, excluding the impact of STELARA, achieved double-digit growth. This strong performance, …

J&J’s DePuy Synthes acquires spine implant maker Expanding Innovations

Johnson & Johnson's DePuy Synthes has acquired Expanding Innovations, a company specializing in expandable implant technology for spine surgery, to strengthen its spine portfolio and expand its presence in the expandable interbody cage segment. Expanding Innovations' proprietary non-screw-based interbody cage technology is designed to …

J&J sees Spravato sales surge as psychedelic competitors loom

Johnson & Johnson's depression drug Spravato saw a 40% Q2 revenue increase, reaching $584 million, marking it as a key franchise with potential peak sales of $5 billion. While psychedelic treatments like Compass Pathways' COMP360 and Definium Therapeutics' DT120 show promising clinical results and …

Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity

Johnson & Johnson (NYSE: JNJ) experienced a nearly 10% stock pullback after its latest earnings report, which analysts view as a buying opportunity due to strong fundamentals and an outlook including revenue surpassing $100 billion. The company reported $25.31 billion in quarterly revenue and …

Johnson & Johnson commits to $55B, 4-year US investment plan

Johnson & Johnson's CFO Joe Wolk announced the company's commitment to a $55 billion, four-year investment plan in the US. Wolk discussed this plan, along with the company's Q2 earnings and the performance of its medical technology unit, including Impella heart pumps, during an …

Johnson & Johnson Earnings: Steady Growth and Good Near-Term Visibility

Johnson & Johnson reported a 6.6% revenue growth in the second quarter, driven by strong performances in Innovative Medicine and MedTech, leading management to increase 2026 guidance. While shares dropped 2% intraday, Morningstar is maintaining its $190 fair value estimate, noting J&J's robust oncology …

Amid $55B US manufacturing push, J&J turns to streamlining its pharma supply chain

Johnson & Johnson is restructuring its pharmaceutical supply chain, announcing up to $750 million in costs to streamline operations, including offloading certain sites. This move follows a $55 billion commitment to bolster U.S. manufacturing capabilities for medicines in the U.S. The company reported strong …

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Johnson & Johnson (NYSE: JNJ) has declared a cash dividend of $1.34 per share for the third quarter of 2026. This dividend will be payable on September 8, 2026, to shareholders recorded by August 25, 2026. The ex-dividend date is also set for August …

Johnson & Johnson posts Q2 2026 earnings beat on medicines unit strength

Johnson & Johnson reported strong Q2 2026 earnings, surpassing expectations with $25.31 billion in sales, primarily driven by its Innovative Medicine unit. The company also raised its full-year revenue outlook to $101.1 billion, a historic milestone. Growth in cancer and immunology drugs offset declines …

Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies

Jefferies notes that strong Q2 sales of Johnson & Johnson's Spravato, a depression treatment, indicate a promising long-term commercial opportunity for psychedelic drugs in treating mental health disorders. The drug's annual revenue run rate of over $2.3 billion and its potential to reach $3 …

J&J raises FY26 outlook following positive Q2

Johnson & Johnson (J&J) reported strong Q2 revenues of $25.3 billion, a 6.6% year-over-year increase, primarily driven by its Innovative Medicine business and J&J MedTech. Following these results, the company raised its 2026 earnings outlook to $11.60-$11.75 per share. Despite the positive outlook, J&J's …

Johnson & Johnson MedTech sales grow 4.5% in Street-beating Q2, ups guidance

Johnson & Johnson (J&J) reported strong Q2 2026 results, surpassing Wall Street expectations with 4.5% growth in MedTech sales and overall sales of $25.3 billion. The company also raised its full-year revenue and adjusted EPS guidance, now expecting annual revenue to exceed $100 billion …

Johnson and Johnson Earnings Report | 2026 Q2 Infographic

Johnson & Johnson released its second-quarter 2026 earnings report, highlighting strong performance in its Innovative Medicine and MedTech businesses. The company reported a 6.6% increase in sales to $25.3 billion, with operational growth of 5.6%, and an adjusted EPS of $2.90. Joe Wolk, EVP …

Johnson & Johnson Hikes Guidance, Stock Falls

Johnson & Johnson exceeded second-quarter earnings and revenue expectations, prompting the company to raise its full-year guidance. This growth was primarily driven by the strong performance of its oncology portfolio, despite a decline in sales for its drug, Stelara. Despite the positive financial results, …

Johnson & Johnson Bumps Up Guidance as Sales Rise

Johnson & Johnson has raised its full-year guidance for sales and adjusted earnings per share after reporting higher sales in the latest quarter. The company now expects full-year sales of $100.8 billion to $101.4 billion and adjusted earnings per share between $11.60 to $11.75, …

Johnson & Johnson $JNJ Shares Sold by Arbejdsmarkedets Tillaegspension

Arbejdsmarkedets Tillaegspension reduced its stake in Johnson & Johnson ($JNJ) by 7.4% in the first quarter, selling 8,626 shares, though the company remains a significant holding for the fund. Despite this, institutional investors broadly hold a large percentage of JNJ's shares, and analysts generally …

Johnson & Johnson presenta sólidos resultados del segundo trimestre, los ingresos y beneficios superan las expectativas y eleva sus previsiones, las acciones en el pre-market caen a contracorriente

Morgan Stanley, Johnson & Johnson And 3 Stocks To Watch Heading Into Wednesday

Morgan Stanley, Johnson & Johnson, Pentair PLC, ASML Holding NV, and Progressive Corp. are among the stocks to watch heading into Wednesday's trading. Morgan Stanley, Johnson & Johnson, and Progressive Corp. are set to release their quarterly earnings reports. Pentair PLC announced a CFO …

Johnson & Johnson (JNJ) approaches earnings after 2.3% weekly setback

The healthcare heavyweight reports July 15, with longer-period gains and lighter turnover making the setup more balanced than the weekly drop alone suggests.

Johnson & Johnson (JNJ) brings a 13.0% four-week climb into July 15 earnings

The Healthcare heavyweight has momentum in weekly context, while lighter volume keeps the pre-results setup from looking fully confirmed.

Johnson & Johnson’s 54.9M-share high tests the limit of an unconfirmed advance

JNJ jumped 11.5% to finish just 0.2% below its 52-week high, but negative activity pressure and a 52% Fair Value premium keep the weekly setup from being one-sided.

Johnson & Johnson (JNJ) insider filing adds an executive acquisition

The update gives investors a fresh ownership datapoint as the drugmaker is viewed through weekly market data rather than live intraday action.

Johnson & Johnson wins FDA approval for expanded Caplyta label

Wolfe Research reiterates Johnson & Johnson stock rating on FDA approval

Johnson & Johnson Remains A Safe Harbor For Investors - Grand Pinnacle Tribune